Mr. Broecker is the President and CEO of the Indiana Biosciences Research Institute (IBRI) focused on improving metabolic health and nutrition. He is an experienced life sciences executive and entrepreneur having founded Zorion Medical, BioCritica, DiaCarta, and now the IBRI. David started his career at Eli Lilly and Company, providing strategic leadership to many of the company’s blockbusters including Prozac and Zyprexa. He is the former President and CEO of Alkermes where his team developed Vivitrol, the first long-acting drug approved for the treatment of alcohol and opiate dependency. David received his undergraduate degree from Wabash College and has graduate degrees from M.I.T. and the University of Chicago.
Douglas Feltner, M.D.
Dr. Feltner is Vice President, Pharmaceutical Development, Neuroscience, AbbVie Inc. where he leads neuroscience development for AbbVie, focusing on projects in Alzheimer‘s disease, Parkinson’s disease, and multiple sclerosis. He has more than 18 years of experience in pharmaceutical drug development and translational medicine, including past positions with Solvay, Warner Lambert and Pfizer, where he was Vice President, Global Head of Translational Medicine. Prior to that he worked on Lyrica® and Chantix®. He has over 40 peer-reviewed scientific publications.
Barbara S. Fox, Ph.D.
Dr. Fox is CEO of Tilos Therapeutics. Tilos is developing novel antibody therapeutics to modulate the immune system for the treatment of cancer, fibrosis and autoimmune diseases. Dr. Fox has broad background in addiction R&D that includes VP Discovery Research of ImmuLogic Pharmaceutical Corp. where she led their cocaine vaccine development program and Recovery Pharmaceuticals, as founder, President and CSO, developing and marketing medications for the treatment of addiction including nicotine dependence products.
Carol A. Gloff, Ph.D.
Dr. Gloff has over 33 years of drug development experience, with responsibilities ranging across nonclinical pharmacology, pharmacokinetic and toxicology programs, early stage clinical studies, chemistry, manufacture and control activities, and development and execution of regulatory strategies for both drugs and biologics. As the founder and principal of Carol Gloff & Associates, for the past 20 years she has advised medical product companies and academic institutes on areas of product development, regulatory affairs, quality, compliance, and specific scientific topics such as pharmacokinetics. Earlier in her career she served as the Vice President of Regulatory Affairs for two pharmaceutical companies, ImmunoGen and Alkermes, and was previously involved in drug/biologic development at Triton Biosciences and formulation development at Pennwalt Pharmaceuticals. In addition to teaching a semester course on regulatory affairs at Boston University for 16 years (1995-2011), from 2005 to 2014 she was an elected member of the Board of Selectmen in Natick, MA, and from 2013 to 2015 she served as President of the University at Buffalo Alumni Association. She is currently a member of the Board of Directors of the American Foundation for Pharmaceutical Education. Dr. Gloff received her B.S. in Pharmacy from the University at Buffalo and her Ph.D. in Pharmaceutical Chemistry, with a concentration in pharmacokinetics, from the University of California San Francisco.
Bruce McCarthy, M.D.
Dr. McCarthy is a drug development and start-up company consultant. Most recently, he was President and CEO of Afferent Pharmaceuticals, a clinical development stage company developing treatments for pain, bladder and respiratory disorders based upon P2X3 antagonism which was purchased by Merck in 2016 transaction valued at $1.25B in cash and contigent payments. His experience includes over 20 years of neuroscience drug development. At Pfizer, Inc., Dr. McCarthy served as vice president, neuroscience development. Clinicians in his organization obtained approval for Chantix® for smoking cessation. Prior to joining Pfizer, he held various roles at Abbott Laboratories, including venture head, where he managed clinical development programs for neuroscience drug candidates, including ABT-594 (an NNR antagonist for pain) and Depakote. He has previously served as an industry consultant, when Dr. McCarthy served as head of development and chief medical officer for several start-up companies including Embera, developing treatments for neurological and psychiatric disorders. Dr. McCarthy received an M.B.A. from Kellogg School of Management, an M.D. from the Johns Hopkins University School of Medicine and a B.S. in biological sciences from Stanford University. He completed his residency in neurology at the University of California, San Francisco.
Jeffrey Ives, Ph.D.
Dr. Ives is a Principal for NeuroPharma Advisors, LLC, a Boston area advisory group dedicated to assisting companies developing therapeutics for central nervous system diseases. From 2008 until 2013, Dr. Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a neurodegenerative disease company focused on discovery and development of breakthrough therapies for the treatment and prevention of Alzheimer’s disease. Prior to Satori, Dr. Ives held numerous senior management and scientific leadership positions at Pfizer. Dr. Ives led the CNS and pain research teams at Pfizer for over two decades and, from 2001 until 2006, served as a Senior Vice President leading the global Pharmacokinetics, Dynamics and Metabolism organization. Dr. Ives received his doctorate and master degrees from Yale University and his bachelor of arts degree from Colgate University.